UCI researchers identify blood biomarkers that may help diagnose, confirm concussions
Findings may lay groundwork for more accurate, timely confirmation of mild traumatic brain injuries
April 20, 2018
Researchers from the University of California, Irvine, Georgetown University and the University of Rochester have found that specific small molecules in blood plasma may be useful in determining whether someone has sustained a mild traumatic brain injury (mTBI), commonly known as a concussion. The article, “Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls,” is now online at the PLOS One journal.
Six specific small molecules from blood plasma were discovered in a group of college athletes who had been diagnosed with concussions. When these molecules were assessed, their combined presence accurately predicted whether teammates had sustained a mTBI or not. This suggests that these small molecules, and possibly others, might be clinically relevant biomarkers of mTBI. The same six biomarkers were then tested in a separate group of individuals, without and with mTBI, and the results replicated the athlete findings.
Although the results are encouraging, the authors report limitations to their study and recommend additional investigations related to these and other mTBI biomarkers in blood that will further clarify their utility in clinical management.
“Such blood tests are important in determining not only whether someone has sustained a concussion, which is not currently an easy task, but may eventually prove useful in defining when injured individuals may be eligible to safely return to regular activities,” said Massimo S. Fiandaca, MD, the paper’s first author, a retired neurosurgeon and co-director of the Georgetown and UCI research groups led by the paper’s senior author, Howard J. Federoff, MD, PhD.
An objective biomarker of mTBI is not yet available to healthcare providers, coaches and trainers, and military commanders and combat medics. Such a diagnostic test might revolutionize the management of civilian and military concussions, including strategies to avoid post-concussive complications and more severe consequences, such as chronic traumatic encephalopathy (CTE). Researchers at UCI are helping advance technologies and therapeutic approaches that may benefit all societies, but are directly relevant to their local populations.
The estimated 40 million individuals worldwide diagnosed with mTBI likely represent a gross underestimation of those actually sustaining such injuries. Clinical practitioners require a relevant and reliable, minimally invasive, objective diagnostic test to determine high versus low probability of mTBI in a timely manner.
Fiandaca said there is a clear need to improve diagnostic capabilities, which could reduce underreporting of mTBI and allow more appropriate care to be delivered to concussed individuals. Falls represent the most common cause associated with mTBI among civilians in the United States and around the world. In the U.S., sport-related mTBI produces up to 3.8 million documented injuries per year. Changes in warfare practices in the last two decades have elevated blast (i.e., explosive) injuries to the primary cause for mTBI in the US active duty military. Between 2000-2016 approximately 82% of all military TBI fell into this category.
Although current technologies for defining the discovered small molecules in today’s publication lack the rapid, point-of-care platforms being developed for other measures, the study authors anticipate a growing technological momentum to develop such novel platforms resulting from this and similar investigations.
This research was supported through a grant from the U.S. Department of Defense to Federoff, initiated while he was at Georgetown in collaboration with investigators from Rochester, and completed at UCI in 2017. In addition to Federoff and Fiandaca, collaborators included Mark Mapstone, PhD, Amin Mahmoodi, Thomas Gross and Fabio Macciardi, MD, PhD, from UCI; Amrita K. Cheema from Georgetown University; and Jeffrey Bazarian, MD, MPH, and Kian Merchant-Borna, MPH, from University of Rochester.
UCI Health comprises the clinical, medical education and research enterprises of the University of California, Irvine. Patients can access UCI Health at physician offices throughout Orange County and at its main campus, UC Irvine Medical Center in Orange, Calif., a 417-bed acute care hospital that provides tertiary and quaternary care, ambulatory and specialty medical clinics, behavioral health and rehabilitation. U.S. News & World Report has listed it among America’s Best Hospitals for 17 consecutive years. UC Irvine Medical Center features Orange County’s only National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program, Level I trauma center and Level II pediatric trauma center, and is the primary teaching hospital for UCI School of Medicine. UCI Health serves a region of more than 3 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on Facebook and Twitter.
About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 30,000 students and offers 192 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit www.uci.edu.